Frentizole

Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus[1][2][3].

Product Specifications

CAS Number

[26130-02-9]

UNSPSC

12352005

Hazard Statement

H302, H319, H413

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Frentizole.html

Purity

99.21

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC=C1)NC2=NC3=CC=C(OC)C=C3S2

Molecular Formula

C15H13N3O2S

Molecular Weight

299.35

Precautions

H302, H319, H413

References & Citations

[1]Meisel AD, et al. Effect of frentizole on mitogen-induced blastogenesis in human lymphocytes. J Immunopharmacol. 1979;1 (4) :483-95.|[2]Walker SE, et al. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole. Arthritis Rheum. 1982 Nov;25 (11) :1291-7.|[3]Yuli Xie, et al. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg Med Chem Lett. 2006 Sep 1;16 (17) :4657-60.